搜索
Search
img

News Center

新闻中心

Kintor pharmaceutical and Sinopharm signed a strategic cooperation agreement

  • Time of issue:2020-04-16

(Summary description)Suzhou Kintor Pharmaceutical ,Inc. ("Kintor Pharmaceutical ")and Sinopharm Holding Co., Ltd. signed the strategic cooperation agreement on the innovation of topical drug Pyrilutamide (KX-826) in Shanghai. Both sides carry out all-round cooperation on patient-centered product design, future business channel development and terminal services, so as to prepare for future market development and better service for patients.

Kintor pharmaceutical and Sinopharm signed a strategic cooperation agreement

(Summary description)Suzhou Kintor Pharmaceutical ,Inc. ("Kintor Pharmaceutical ")and Sinopharm Holding Co., Ltd. signed the strategic cooperation agreement on the innovation of topical drug Pyrilutamide (KX-826) in Shanghai. Both sides carry out all-round cooperation on patient-centered product design, future business channel development and terminal services, so as to prepare for future market development and better service for patients.

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2020-04-16 09:20
  • Views:
Information
[Shanghai, April 16, 2020] Suzhou Kintor Pharmaceutical ,Inc. ("Kintor Pharmaceutical ")and Sinopharm Holding Co., Ltd. signed the strategic cooperation agreement on the innovation of topical drug Pyrilutamide (KX-826) in Shanghai. Both sides carry out all-round cooperation on patient-centered product design, future business channel development and terminal services, so as to prepare for future market development and better service for patients.
Representatives of the two sides signed the strategic agreement
Leaders and colleagues from Kintor and Sinopharm witnessed the signing
Suzhou Kintor Pharmaceutical ,Inc. 's independent research and development of China and the United States double reported double batch of innovative drug Pyrilutamide is used for the treatment of androgenic alopecia, androgen receptor antagonist, is undergoing phase II clinical trials in China and phase Ib clinical trials in the United States. With the rapid advance of clinical research, in order to fully prepare for the drug market and patient service, the development of the pharmaceutical industry and China's largest pharmaceutical distributor to cooperate with the commercial layout, for the development of China's hair loss field of the blue ocean market.
At present, there are a large number of people with hair loss, and the growth of hair transplantation and wig industry is booming, but the really safe and effective drug treatment methods are far from meeting the needs of patients. Up to now, the main treatment methods of androgenic alopecia areata in the world are Minoxidil and Finasteride. Local application of Minoxidil lacks a clear mechanism of action, while oral application of Finasteride, due to its sex-related side effects, has prevented a large number of patients from choosing it as the treatment of hair loss. Pyrilutamide is a targeted drug designed for topical use, which ACTS directly on the scalp at targeted therapeutic sites. Based on the latest data from pharmacologic studies and clinical trials, it has not shown adverse side effects, so we believe that Pyrilutamide has the potential to attract more patients with hair loss than existing treatment regimens and redefine the market for hair loss drugs.

Scan the QR code to read on your phone

News Center

Company News    Media Reports

Contact Us

Find Us

这是描述信息